Entera Bio (ENTX) Other Non-Current Liabilities (2025)
Entera Bio (ENTX) posted quarterly Other Non-Current Liabilities of $393000.0 for Q4 2025.
Entera Bio (ENTX) Other Non-Current Liabilities (2025) Analysis & Trends
Entera Bio (ENTX) has reported Other Non-Current Liabilities for 1 consecutive years, with $393000.0 the latest figure, recorded in Q4 2025.
- Quarterly Other Non-Current Liabilities changed N/A year-over-year to $393000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $393000.0 (changed N/A YoY) and the FY2025 annual result came in at $393000.0, changed N/A from the prior year.
- Other Non-Current Liabilities held at $393000.0 in Q4 2025 per ENTX's latest filing.
- Over the last five years, Other Non-Current Liabilities for ENTX reached as high as $393000.0 in Q4 2025 and fell as low as $393000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Entera Bio | 186.78 Mn | 182.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 393,000.00 |